We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cancer-Causing Protein May Restore Spinal Cord, Brain Cells

By Biotechdaily staff writers
Posted on 12 Jul 2006
Scientists have discovered that a protein known for triggering the growth of cancer also plays an unexpected role in restoring the ability of neurons to regenerate, making it a significant target for tackling spinal cord damage or neurologic disorders such as diseases like Alzheimer's disease.

The study was published in the journal Nature's website on June 28, 2006, and will be published in an upcoming issue. More...
"Our finding suggests that the same process this protein uses for proliferating cancer could also potentially be used to regenerate axons that are damaged in spinal cord injuries or neurological diseases,” said Antonio Iavarone, M.D., associate professor of neurology and pathology at Columbia University Medical Center's (New York, NY, USA) Institute for Cancer Genetics, and the study's lead author. The proteins, called Id (idiotype) proteins, are plentiful in the cells of many different types of cancer, including brain, breast, and pediatric tumors, and were known to promote tumor growth and contribute to the spread of cancer.

While looking for ways to attack Id's cancer-causing properties, Dr. Iavarone and Anna Lasorella, M.D., assistant professor of pediatrics and pathology at the Institute for Cancer Genetics, found the surprising neuron-healing properties of Id proteins. Their early results, also published in the Nature study, are important for potential cancer therapies. The researchers found that an enzyme inside normal cells, called adenomatous polyposis coli (APC), typically degrades Id proteins soon after they are produced, but cancerous cells demonstrate a very high level of Id proteins. This suggests that re-introducing the APC enzyme into cancer cells could eliminate the proteins and arrest the growth of tumor cells, something that researchers will now further examine.

Among neurons, however, the researchers assessed the Id protein potential for promoting growth, instead of suppressing it. The researchers wanted to use the power of Id proteins to stimulate growth of axons--the structures on neurons responsible for transmitting electrical signals in the brain and spinal cord. However, to do that they needed to solve the problem of the APC enzyme, which degrades the protein in healthy cells. So they devised a "super” Id protein that would resist degradation from the APC enzyme, allowing it to promote axonal growth.

Usually, neurons cannot regenerate damaged axons because of the presence of myelin, a substance that surrounds the axons, but the degradation-resistant "super” Id protein was able to promote axon growth even in the presence of myelin. Dr. Iavarone also noted that there is no possibility that such a therapy would cause cancer in the brain or spinal cord. "Neurons have completely lost the ability to create new cells so there's no danger of creating a tumor. The only growth they're capable of is regeneration of their axons,” he said.



Related Links:
Columbia University Medical Center

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.